22-17209533-GC-GCC
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001282225.2(ADA2):βc.144_145insGβ(p.Arg49AlafsTer13) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000161 in 1,613,064 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000013 ( 0 hom., cov: 31)
Exomes π: 0.000016 ( 0 hom. )
Consequence
ADA2
NM_001282225.2 frameshift
NM_001282225.2 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.668
Genes affected
ADA2 (HGNC:1839): (adenosine deaminase 2) This gene encodes a member of a subfamily of the adenosine deaminase protein family. The encoded protein is one of two adenosine deaminases found in humans, which regulate levels of the signaling molecule, adenosine. The encoded protein is secreted from monocytes undergoing differentiation and may regulate cell proliferation and differentiation. This gene may be responsible for some of the phenotypic features associated with cat eye syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 22-17209533-G-GC is Pathogenic according to our data. Variant chr22-17209533-G-GC is described in ClinVar as [Likely_pathogenic]. Clinvar id is 586963.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ADA2 | NM_001282225.2 | c.144_145insG | p.Arg49AlafsTer13 | frameshift_variant | 2/10 | ENST00000399837.8 | NP_001269154.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ADA2 | ENST00000399837.8 | c.144_145insG | p.Arg49AlafsTer13 | frameshift_variant | 2/10 | 1 | NM_001282225.2 | ENSP00000382731 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151910Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
2
AN:
151910
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1461154Hom.: 0 Cov.: 34 AF XY: 0.0000151 AC XY: 11AN XY: 726908
GnomAD4 exome
AF:
AC:
24
AN:
1461154
Hom.:
Cov.:
34
AF XY:
AC XY:
11
AN XY:
726908
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151910Hom.: 0 Cov.: 31 AF XY: 0.0000270 AC XY: 2AN XY: 74186
GnomAD4 genome
AF:
AC:
2
AN:
151910
Hom.:
Cov.:
31
AF XY:
AC XY:
2
AN XY:
74186
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Oct 25, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2023 | - - |
Vasculitis due to ADA2 deficiency Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 14, 2023 | This sequence change creates a premature translational stop signal (p.Arg49Alafs*13) in the ADA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ADA2 are known to be pathogenic (PMID: 24552284, 24552285). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with ADA2 deficiency (PMID: 27514238). ClinVar contains an entry for this variant (Variation ID: 586963). For these reasons, this variant has been classified as Pathogenic. - |
Sneddon syndrome;C3887654:Vasculitis due to ADA2 deficiency Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 18, 2022 | - - |
Splenomegaly Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Immunogenetics Laboratory, Johns Hopkins All Children's Hospital | Apr 19, 2018 | The Arg49Alafs*13 variant has been reported in two cases with hemolytic anemia or CVID like presentation (Tal Ben-Ami 2016). Additionally, ADA2 protein level was extremely low in our CVID patient with this variant. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at